• Orion and Bayer seek marketing clearance for darolutamide in Japan pharmaceutical-technology
    March 06, 2019
    Orion and Bayer have submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking marketing authorisation for darolutamide to be applied in the treatment castration-resistant prostate cancer (CRPC).
PharmaSources Customer Service